HealthEquity, Inc. (NASDAQ:HQY – Get Free Report) EVP Michael Henry Fiore sold 3,142 shares of the business’s stock in a transaction on Friday, May 29th. The stock was sold at an average price of $95.00, for a total transaction of $298,490.00. Following the completion of the sale, the executive vice president directly owned 59,113 shares of the company’s stock, valued at approximately $5,615,735. The trade was a 5.05% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
HealthEquity Price Performance
Shares of NASDAQ HQY opened at $86.00 on Friday. The firm has a market cap of $7.19 billion, a PE ratio of 32.21, a PEG ratio of 1.46 and a beta of 0.21. The firm has a fifty day moving average of $83.93 and a 200 day moving average of $86.31. The company has a debt-to-equity ratio of 0.46, a quick ratio of 3.44 and a current ratio of 3.44. HealthEquity, Inc. has a one year low of $72.76 and a one year high of $116.65.
HealthEquity (NASDAQ:HQY – Get Free Report) last issued its quarterly earnings results on Thursday, May 28th. The company reported $1.24 EPS for the quarter, topping the consensus estimate of $1.11 by $0.13. HealthEquity had a net margin of 17.25% and a return on equity of 14.75%. The company had revenue of $354.64 million during the quarter, compared to analyst estimates of $352.02 million. The company’s revenue was up 7.2% on a year-over-year basis. HealthEquity has set its FY 2027 guidance at 2.880-2.950 EPS. As a group, research analysts predict that HealthEquity, Inc. will post 3.86 EPS for the current fiscal year.
Institutional Inflows and Outflows
Analyst Upgrades and Downgrades
HQY has been the subject of a number of research reports. UBS Group set a $110.00 target price on shares of HealthEquity in a report on Tuesday, February 17th. KeyCorp reaffirmed an “overweight” rating on shares of HealthEquity in a report on Tuesday, May 26th. JPMorgan Chase & Co. dropped their target price on shares of HealthEquity from $129.00 to $123.00 and set an “overweight” rating for the company in a report on Wednesday, March 18th. Deutsche Bank Aktiengesellschaft upped their target price on shares of HealthEquity from $120.00 to $128.00 and gave the stock a “buy” rating in a report on Thursday, March 19th. Finally, Barclays lowered their price target on shares of HealthEquity from $118.00 to $110.00 and set an “overweight” rating on the stock in a research report on Wednesday, February 18th. One investment analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $110.57.
About HealthEquity
HealthEquity, Inc (NASDAQ: HQY) is a leading administrator of consumer-directed health accounts and related benefit solutions in the United States. Founded in 2002 and headquartered in Draper, Utah, the company specializes in health savings accounts (HSAs) and offers complementary services such as flexible spending accounts (FSAs), health reimbursement arrangements (HRAs), COBRA administration and commuter benefits. Through its technology-driven platform, HealthEquity enables employers, health plans and individuals to streamline account management, improve cost transparency and encourage more informed healthcare spending.
Serving millions of members across all 50 states, HealthEquity leverages an open-architecture ecosystem that integrates with health plans, payroll providers and financial institutions.
Further Reading
- Five stocks we like better than HealthEquity
- The Great AI Server Rotation Puts Hewlett Packard Enterprise and Super Micro Computer in Focus
- Generac’s AI Power Pivot Raises a Bigger Question About Data Center Demand
- Medtronic Bottoms, Healthy Rebound Ahead
- GitLab’s Price Recovery Gains Traction—Time to Get On Board?
Receive News & Ratings for HealthEquity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HealthEquity and related companies with MarketBeat.com's FREE daily email newsletter.
